Navigation Links
MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Date:9/10/2009

sponse and side effects such as heightened blood pressure.

Common symptoms of migraine include recurrent headaches, nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound). According to the National Headache Foundation, most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly, according to published studies. Migraine patients often report that currently approved drugs do not fully meet their needs due to slow onset of action, short duration of effect, inconsistent response and unacceptable side effect profiles. The economic burden of migraine remains substantial despite existing treatments, with the direct and indirect costs of migraine in the United States estimated at over $20 billion annually.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

LEVADEX and TEMPO are trademarks of MAP Pharmaceuticals, Inc.

Forward-Looking Statements


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Mass. , July 31, 2014 /PRNewswire/ ... funding changes brought about by the Affordable ... reimbursement and prescribing of pharmaceutical therapies. The ... cover beneficiaries through new regulations and expanded ... occurring in the health exchanges—state-based marketplaces set ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
(Date:7/31/2014)... COLORADO SPRINGS, Colo. , July 31, 2014 ... Company specializing in cannabis formulation-based drug development and ... has commenced production of multiple strains of cannabis ... scientific research to select the best strains for ... to bring the cannabis formulations to market for ...
Breaking Medicine Technology:Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Lazarus Effect Closes $5 Million Financing 2Cannabis Science Initiates Scientific Cultivation Programs to Test Multiple Strains of Cannabis to Obtain Extract Formulations for Clinical Drug Development Targeting Multiple Critical Ailments Starting with Cancer and Neurological Disorders 2
... Nov. 19 A recent Reuters article reported ... expect an industry increase as a result of broader insurance ... million additional Americans may begin receiving health care insurance coverage ... on the access" extended to the new enrollees according to ...
... , NEW YORK, Nov. 19 Delcath Systems, Inc. ... Delcath Percutaneous Hepatic Perfusion (PHP(TM)) System, a minimally invasive drug ... the liver, today reported on the Company,s recent progress. , ... our team has achieved many significant milestones as we move ...
Cached Medicine Technology:Delcath Systems Reports Substantial Progress 2Delcath Systems Reports Substantial Progress 3Delcath Systems Reports Substantial Progress 4
(Date:7/31/2014)... WA (PRWEB) July 31, 2014 Just ... Duke’s Chowder House is featuring new summertime ... at all six Duke’s locations throughout the ... out-of-town guests alike, Duke’s award-winning, customer-nominated Seattle’s best happy ... decks. To celebrate its Lake Union location’s 25th anniversary ...
(Date:7/31/2014)... PHILADELPHIA Women who recently used birth control pills ... an increased risk for breast cancer, whereas women using ... in Cancer Research , a journal of the ... that use of contemporary oral contraceptives [birth control pills] ... breast cancer risk relative to never or former oral ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Hoping to attract ... they can trust , NutriGold is ready to ship ... up to make taking advantage of this offer fast and ... of Research and Development at NutriGold, "We know that every ... us with their most precious asset: their own health or ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 In many states ... required for proper storage of necessary life saving drugs. This ... Unfortunately there is still a high number of ambulances without ... EMT who steals the narcotics and even replaces the vital ... receives none. As seen in the case in Baraboo, Wisconsin ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Niche Profit Classroom, ... Short that is designed to provide a blueprint for anyone ... attention of Shane Michaels, prompting an investigative review. , ... “What really speaks volumes about the success of the information ... strategies included in it have stayed effective even through all ...
Breaking Medicine News(10 mins):Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 2Health News:Seattle Seafood Restaurant Lake Union Duke's Chowder House Celebrating its 25th Anniversary, Still a Best Outdoor Deck Spot to Sip Up Cocktails in Record-Breaking Heat. 3Health News:Recent use of some birth control pills may increase breast cancer risk 2Health News:NutriGold Launches Product Samples Page for its Supplements 2Health News:NutriGold Launches Product Samples Page for its Supplements 3Health News:New MedixSafe Alert - Ambulances Must Have A Medical Safe, Narcotics Cabinet, or Drug Locker 2Health News:Niche Profit Classroom: Review Exposes Adam Short’s Guide to Building Niche Websites 2
... Window from 12 Days to 27 Hours , ... the leading provider of Windows file server virtualization solutions, ... center for medical research and treatment, has deployed its ... efficiency of its Windows data replication operations. Since ...
... TSX: COM,VANCOUVER, May 19 /PRNewswire-FirstCall/ - Cardiome Pharma ... the waiting period under the Hart-Scott-Rodino Act for the ... and a Merck affiliate for development and commercialization of ... fibrillation, has expired, and the agreement is now effective. ...
... internally dynamized anterior cervical plating system offers zero-step ... Spine announces the nationwide market introduction of the ... which gained 510(k) approval from the U.S. Food ... an internally dynamizing anterior cervical plating ...
... 19 Capturing vividly the core message of HealthCorps, ... Just DNA" was successfully auctioned at The Green Garden ... Chairman, and his wife Lisa Oz, at the World ... Thetford, who made the impressive four-figure winning bid, commented, ...
... offer the online social network the chance to meet ... in at the site, topics of interest to be ... FertilityTies ( www.FertilityTies.com ), the most ... to conceive/facing infertility that combines expertise of accredited MDs, ...
... Clearly Now" Helps Readers Seek Deeper Meaning in Their ... Soliel,s debut non-fiction, "I Can See Clearly Now: How ... Finalist in the "Spirituality" category of the 2009 National ... book was previously selected by USA Book News as ...
Cached Medicine News:Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 2Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 3Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 4Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 2Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 3Health News:Artist Neera Dahiya Featured at Silent Auction Held During HealthCorps' Green Garden Gala 2Health News:Artist Neera Dahiya Featured at Silent Auction Held During HealthCorps' Green Garden Gala 3Health News:FertilityTies.com Convention Open to the Public, June 6, 1-5 PM at The Hilton New York Hotel, MDs to Lead Discussion on Timely Fertility Topics 2Health News:Author Mary Soliel Receives Third National Book Award for Debut Non-Fiction on Synchronicity 2Health News:Author Mary Soliel Receives Third National Book Award for Debut Non-Fiction on Synchronicity 3
... is an internationally known brand famous ... The ophthalmic collection offers chic and ... creativity in titanium, metal and plastic ... unique styling with trendy shapes and ...
... The license agreement between Brook ... to 1993. Characterized by lightweight materials ... Brothers collections reflect the unique features ... brand. A product with classic style ...
... style. Creativity and cutting-edge design. Dolce & ... a new licensing agreement in October 2005.The ... 1985 by the famous designer duo, Domenico ... with their Mediterranean roots to create the ...
Michael Kors eyewear delivers chic American style, updated for today's discerning high-end consumer.,Made from the finest materials, the eyewear collection artfully mixes textures and fabrications, c...
Medicine Products: